A Natali, S Baldeweg, E Toschi, B Capaldo, D … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a randomized, double-blind design, we assigned
74 type 2 diabetic patients to rosiglitazone (8 mg/day), metformin (1,500 mg/day), or placebo
treatment for 16 weeks and measured insulin sensitivity (euglycemic insulin clamp), ... Cited by 130 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org F Pistrosch, J Passauer, S Fischer, K Fuecker, M … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Glycemic control was comparable under rosiglitazone and nateglinide. Rosiglitazone
ameliorated insulin resistance by 60% compared with nateglinide. ACh response was significantly
increased after rosiglitazone treatment (maximum forearm blood flow 12.8 ± 1.3 vs. 8.8 ± ... Cited by 175 - Related articles - BL Direct - All 5 versions
M Shargorodsky, G Wainstein, E Gavish, Z … - American Journal of …, 2003 - Elsevier In an open label study 52 patients with non-insulin dependent diabetes mellitus and at least
one additional cardiovascular risk factor, were treated for 6 months with 4 mg of
rosiglitazone, and uptitrated to 8 mg after 3 months of treatment, if needed. At the ... Cited by 52 - Related articles - All 6 versions
TD Wang, WJ Chen, JW Lin, MF Chen, YT Lee - The American journal of …, 2004 - Elsevier Fifty nondiabetic patients who met a modified National Cholesterol Education Program definition
for the metabolic syndrome were randomized to receive either rosiglitazone (4 mg/day; N =
25) or placebo (n = 25) for 8 weeks. Compared with those receiving placebo, patients in ... Cited by 152 - Related articles - All 10 versions
C Yosefy, E Magen, A Kiselevich, R Priluk, D … - Journal of …, 2004 - journals.lww.com Background: Type II diabetes is often associated with high blood pressure, elevated sympathetic
activity, and high plasma insulin lev- els. Hypoglycemic agents may negatively interfere with
blood pres- sure control, sympathetic activity, and plasma insulin level; therefore the ... Cited by 49 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org [PDF] SY Honisett, L Stojanovska, K Sudhir, BA Kingwell, … - Diabetes Care, 2003 - Am Diabetes Assoc T ype 1 diabetes is associated with other autoimmune diseases. Many diabetes centers routinely
screen patients with type 1 diabetes for auto- immune thyroid disease (ATD). The pres- ence
of two autoimmune diseases raises the possibility of polyendocrine auto- immune ... Cited by 42 - Related articles - BL Direct - All 5 versions
SMA Bennett, A Agrawal, H Elasha, M Heise, … - Diabetic …, 2004 - interscience.wiley.com Methods Eighteen subjects with persistent IGT were randomized to receive rosiglitazone 4 mg
twice daily or matching placebo for 12 weeks. Evaluation at baseline and at the end of treatment
included measurement of whole body insulin sensitivity during a euglycaemic ... Cited by 69 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org M St John Sutton, M Rendell, P Dandona, JF Dole, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg
bid) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to
limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram ... Cited by 219 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org N Satoh, Y Ogawa, T Usui, T Tagami, S Kono, H … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 136 Japanese type 2 diabetic patients were
included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3
months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid ... Cited by 254 - Related articles - BL Direct - All 5 versions
PA Sarafidis, AN Lasaridis, PM Nilsson, EM … - Journal of …, 2004 - journals.lww.com Page 1. Ambulatory blood pressure reduction after rosiglitazone treatment in patients
with type 2 diabetes and hypertension correlates with insulin sensitivity increase
Panteleimon A. Sarafidisa, Anastasios N. Lasaridisa, Peter M. Nilssonb, ... Cited by 67 - Related articles - BL Direct - All 5 versions
